Can You Take MOTS-C and Semaglutide Together?

What MOTS-C is — and where the evidence runs out

MOTS-C (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a small peptide encoded in mitochondrial DNA. Preclinical research, largely in rodent models, has linked it to improved insulin sensitivity, mitochondrial efficiency and reduced fat accumulation. A small number of early human studies have looked at circulating MOTS-C levels in relation to ageing and metabolic conditions, but none have tested supplemental MOTS-C as a therapeutic agent in a properly powered randomised controlled trial in humans. The peptide is not approved as a medicine by the MHRA, the EMA or the FDA, and it has no licensed clinical indication in the UK. It circulates primarily as an injectable research compound, sold through grey-market suppliers — a supply chain that carries its own significant quality and purity risks. For now, the science sits firmly in the exploratory phase.

That context matters enormously when the question is whether it is safe to add MOTS-C to an existing course of semaglutide. The honest answer is: nobody knows, because the combination has not been studied.

How semaglutide works, and why its interactions matter

Semaglutide, the active ingredient in Wegovy, activates GLP-1 receptors in the brain and gut, reducing appetite and slowing gastric emptying. Those effects are well-characterised across large clinical programmes. The STEP 1 trial published in the New England Journal of Medicine randomised over 1,900 adults and found an average weight reduction of around 15% over 68 weeks at the 2.4 mg maintenance dose. The NHS has a detailed medicines page covering semaglutide's known interactions, side effects and contraindications, which is the right starting point for anyone reviewing what semaglutide does and does not combine safely with.

Because semaglutide slows gastric emptying, it can alter how quickly other orally ingested substances are absorbed. For injected peptides like MOTS-C this pathway is less relevant, but the broader concern remains: two compounds that both influence metabolic and hormonal signalling could interact in ways that are not predictable without data. Overlapping effects on insulin sensitivity, in particular, could in theory compound hypoglycaemic risk in certain patients, though this is speculative given the absence of trials.

If you are curious about the ways semaglutide interacts with other substances, our page on semaglutide and Accutane together illustrates how the same principles apply across very different drug classes.

The regulatory gap and what it means in practice

The UK regulatory framework treats semaglutide and MOTS-C in fundamentally different ways. Semaglutide is a Black Triangle (▼) Prescription-Only Medicine, meaning it carries additional MHRA monitoring requirements and every supply must follow a clinical assessment. The NHS medicines page for semaglutide lists approved interactions and safety signals. MOTS-C has no equivalent regulatory home in the UK; there is no patient information leaflet, no approved prescribing information, no pharmacovigilance database collecting reports of adverse effects from its use.

That asymmetry creates a practical problem. When a combination produces an unexpected effect, there is no framework to determine whether MOTS-C, semaglutide, their interaction, or an unrelated factor caused it. Reporting a suspected problem via the MHRA Yellow Card scheme is always encouraged for any reaction linked to a licensed medicine, but the MOTS-C side of the equation remains invisible to regulators.

Some people looking at peptide combinations alongside weight-loss medicines also ask about combining different licensed GLP-1 agents, something like taking Saxenda and Wegovy together is a separate and equally important safety question, worth reading if you are considering any dual-GLP-1 approach.

A note on timing: if you are mid-course on semaglutide and wondering whether to add a research compound before, say, a holiday or a break in your routine, that is exactly the kind of change worth discussing with a prescriber first rather than afterwards.

What to do if you want to use both

The practical step is straightforward: tell your prescribing clinician everything you are taking, including supplements, research peptides and over-the-counter preparations. A prescriber who does not know about MOTS-C cannot factor it into their clinical assessment. At nume, a named GPhC-registered Independent Prescriber reads every consultation personally. There is no automated triage; a real clinician reviews your answers the same day and can flag concerns about unlicensed compounds before any treatment is dispatched.

The semaglutide information page is a useful reference for understanding the licensed medicine's full profile. For those weighing the broader landscape of weight management options, the weight-loss overview covers what is licensed and clinically assessed in the UK. If you are curious about how semaglutide affects areas of physiology that researchers are still exploring, our page on semaglutide and the gut microbiome covers one such area with the same evidence-first approach. Cost is sometimes a factor in decisions about what to add to a regimen; the Wegovy price guide sets out what private treatment actually involves.

If you are ready to discuss your full picture with a clinician, you can speak to our prescribers through a free consultation at the treatment page.